Skip to main content

Advertisement

SpringerLink
Log in

Research progress of astragaloside IV in treating acute kidney injury

  • Nephrology - Review
  • Published:
International Urology and Nephrology Aims and scope Submit manuscript

Abstract

Acute kidney injury (AKI) is one of the most common clinical critical illnesses, with decreased glomerular filtration rate, retention of nitrogen products, water and electrolyte disorders, and acid–base imbalance as the main clinical manifestations. Presently, there is no effective treatment for acute kidney injury, but the main treatment is to cure the primary disease, remove risk factors, maintain acid–base and water–electrolyte balance, and undergo kidney replacement. However, the mortality rate is still high. Investigations and studies showed that the mortality rate of patients with acute kidney injury in the ICU is 5–80% [1]. In recent years, Chinese medicine has been widely used in acute kidney injury treatment due to its complete dialectical system and rich experience. Astragalus is a commonly used medicine in traditional Chinese medicine to treat acute kidney injury. Astragaloside IV is the main active component of traditional Chinese medicine, Astragalus membranaceus. This article summarizes the relevant studies on treating acute kidney injury with astragaloside IV.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

Data Availability

The dataset(s) supporting the conclusions of this article are available in the pubmed (https://www.ncbi.nlm.nih.gov/).

References

  1. Santos RPD, Carvalho ARS, Peres LAB, Ronco C, Macedo E (2019) An epidemiologic overview of acute kidney injury in intensive care units. Rev Assoc Med Bras (1992) 65(8):1094–1101

    Article  PubMed  Google Scholar 

  2. Waikar SS, Curhan GC, Ron W et al (2006) Declining mortality in patients with acute renal failure, 1998 to 2002. J Am Soc Nephrol Jasn 17(4):1143

    Article  PubMed  Google Scholar 

  3. Lewington AJ, Cerdá J, Mehta RL (2013) Raising awareness of acute kidney injury: a global perspective of a silent killer. Kidney Int 84(3):457–467

    Article  PubMed  PubMed Central  Google Scholar 

  4. Susantitaphong P, Cruz DN, Cerda J et al (2013) World incidence of AKI: a meta-analysis. Clin J Am Soc Nephrol 8:1482–1493

    Article  PubMed  PubMed Central  Google Scholar 

  5. Li PK, Burdmann EA, Mehta RL (2013) World Kidney Day Steering Committee 20 Acute kidney injury: global health alert. Transplantation 95:653–657

    Article  PubMed  CAS  Google Scholar 

  6. Shao G, He J, Meng J, Ma A, Geng X, Zhang S, Qiu Z, Lin D, Li M, Zhou H, Lin S, Yang B (2021) Ganoderic acids prevent renal ischemia-reperfusion injury by inhibiting inflammation and apoptosis. Int J Mol Sci 22(19):10229

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  7. Keir I, Kellum JA (2015) Acute kidney injury in severe sepsis: pathophysiology, diagnosis, and treatment recommendations. J Vet Emerg Crit Care (San Antonio) 25(2):200–209

    Article  PubMed  Google Scholar 

  8. Feng L, Xiong Y, Cheng F, Zhang L, Li S, Li Y (2004) Effect of ligustrazine on ischemia-reperfusion injury in murine kidney. Transplant Proc 36(7):1949–1951

    Article  PubMed  CAS  Google Scholar 

  9. Lan Z, Bi KS, Chen XH (2014) Ligustrazine attenuates elevated levels of indoxyl sulfate, kidney injury molecule-1, and clusterin in rats exposed to cadmium. Food Chem Toxicol 63:62–68

    Article  PubMed  CAS  Google Scholar 

  10. Chen G, Fu Y, Wu X (2012) Protective effect of Salvia miltiorrhiza extract against renal ischemia-reperfusion-induced injury in rats. Molecules 17(2):1191–1202

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  11. Chen T, Zhan L, Fan Z, Bai L, Song Y, Lu X (2016) Efficacy of Chinese herbal medicine as an adjunctive therapy on in-hospital mortality in patients with acute kidney injury: a systematic review and meta-analysis. Evid Based Complement Alternat Med 2016:7592705

    Article  PubMed  PubMed Central  Google Scholar 

  12. Fu J, Wang Z, Huang L, Zheng S, Wang D, Chen S, Zhang H, Yang S (2014) Review of the botanical characteristics, phytochemistry, and pharmacology of Astragalus membranaceus (Huangqi). Phytother Res 28(9):1275–1283

    Article  PubMed  CAS  Google Scholar 

  13. Li X, Qu L, Dong Y, Han L, Liu E, Fang S, Zhang Y, Wang T (2014) A review of recent research progress on the astragalus genus. Molecules 19(11):18850–18880

    Article  PubMed  PubMed Central  Google Scholar 

  14. Shan H, Zheng X, Li M (2019) The effects of astragalus membranaceus active extracts on autophagy-related diseases. Int J Mol Sci 20(8):1904

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  15. Ren S, Zhang H, Mu Y, Sun M, Liu P (2013) Pharmacological effects of Astragaloside IV: a literature review. J Tradit Chin Med 33(3):413–416

    Article  PubMed  Google Scholar 

  16. Zhou X, Sun X, Gong X, Yang Y, Chen C, Shan G, Yao Q (2017) Astragaloside IV from Astragalus membranaceus ameliorates renal interstitial fibrosis by inhibiting inflammation via TLR4/NF-кB in vivo and in vitro. Int Immunopharmacol 42:18–24

    Article  PubMed  CAS  Google Scholar 

  17. Qi W, Niu J, Qin Q, Qiao Z, Gu Y (2014) Astragaloside IV attenuates glycated albumin-induced epithelial-to-mesenchymal transition by inhibiting oxidative stress in renal proximal tubular cells. Cell Stress Chaperones 19(1):105–114

    Article  PubMed  CAS  Google Scholar 

  18. Li L, Hou XJ, Xu RF, Liu C, Tu M (2017) Research review on the pharmacological effects of astragaloside IV. Fundam Clin Pharmacol 31:17–36

    Article  PubMed  CAS  Google Scholar 

  19. Zhou W, Chen Y, Zhang X (2017) Astragaloside IV alleviates lipopolysaccharide-induced acute kidney injury through down-regulating cytokines, CCR5, and p-ERK, and elevating anti-oxidative ability. Med Sci Monit 22(23):1413–1420

    Article  Google Scholar 

  20. Tan S, Wang G, Guo Y, Gui D, Wang N (2013) Preventive effects of a natural anti-inflammatory agent, astragaloside IV, on ischemic acute kidney injury in rats. Evid Based Complement Alternat Med 2013:284025

    Article  PubMed  PubMed Central  Google Scholar 

  21. Yan W, Xu Y, Yuan Y, Tian L, Wang Q, Xie Y, Shao X, Zhang M, Ni Z, Mou S (2017) Renoprotective mechanisms of Astragaloside IV in cisplatin-induced acute kidney injury. Free Radic Res 51(7–8):669–683

    Article  PubMed  CAS  Google Scholar 

  22. Gui D, Huang J, Liu W, Guo Y, Xiao W, Wang N (2013) Astragaloside IV prevents acute kidney injury in two rodent models by inhibiting oxidative stress and apoptosis pathways. Apoptosis 18(4):409–422

    Article  PubMed  CAS  Google Scholar 

  23. Murata I, Abe Y, Yaginuma Y, Yodo K, Kamakari Y, Miyazaki Y, Baba D, Shinoda Y, Iwasaki T, Takahashi K, Kobayashi J, Inoue Y, Kanamoto I (2017) Astragaloside-IV prevents acute kidney injury and inflammation by normalizing muscular mitochondrial function associated with a nitric oxide protective mechanism in crush syndrome rats. Ann Intensive Care 7(1):90

    Article  PubMed  PubMed Central  Google Scholar 

  24. Morigi M, Imberti B, Zoja C, Corna D, Tomasoni S, Abbate M, Rottoli D, Angioletti S, Benigni A, Perico N, Alison M, Remuzzi G (2004) Mesenchymal stem cells are renotropic, helping to repair the kidney and improve function in acute renal failure. J Am Soc Nephrol 15(7):1794–1804

    Article  PubMed  Google Scholar 

  25. Yan J, Wei W, Zezheng L, Jin C, Weiwei W, Jinyuan Z (2014) The Protection of the transplantation of Ast - hADSC in cisplatin-induced Acute kidney injury. Chin J Integr Tradit West Nephrol 15(2):114–117

    Google Scholar 

  26. Song Y, Hu T, Gao H, Zhai J, Gong J, Zhang Y, Tao L, Sun J, Li Z, Qu X (2020) Altered metabolic profiles and biomarkers associated with astragaloside IV-mediated protection against cisplatin-induced acute kidney injury in rats: an HPLC-TOF/MS-based untargeted metabolomics study. Biochem Pharmacol 24(183):114299

    Google Scholar 

  27. Qu X, Gao H, Tao L, Zhang Y, Zhai J, Sun J, Song Y, Zhang S (2019) Astragaloside IV protects against cisplatin-induced liver and kidney injury via autophagy-mediated inhibition of NLRP3 in rats. J Toxicol Sci 44(3):167–175

    Article  PubMed  CAS  Google Scholar 

  28. Feng M, Lv J, Zhang C, Chen D, Guo H, Tu Y, Su L, Wang Z (2022) Astragaloside IV protects sepsis-induced acute kidney injury by attenuating mitochondrial dysfunction and apoptosis in renal tubular epithelial cells. Curr Pharm Des 28(34):2825–2834

    Article  PubMed  CAS  Google Scholar 

Download references

Funding

This work is funded by National Nature Science Foundation of China (8210483), Sponsored by Natural Science Foundation of Sichuan,China (2022YFS0398), and Guangdong Province Higher Education Scientific and Technological Innovation (Key) Project (2021ZDZX2038).

Author information

Author notes

  1. Youqun Huang and Dongxuan Sun are co first authors.

Authors and Affiliations

  1. Department of Nephrology, Health Science Center, South China Hospital, Shenzhen University, No.1, Fuxin Road, Longgang District, Shenzhen, People’s Republic of China

    Yu Liu, Dongxuan Sun, Tong Chen & Li Zhou

  2. Guangdong Key Laboratory for Biomedical Measurements and Ultrasound, ImagingSchool of Biomedical Engineering, Shenzhen University Health Science Center, Shenzhen, 518060, China

    Yu Liu

  3. Department of Nephrology, Hospital of Chengdu University of Traditional Chinese Medicine, No.39, Shierqiao Road, Jinniu District, Chengdu, Sichuan, China

    Youqun Huang, Naijing Ye & Mengfan Yang

  4. The Chinese University of Hong Kong, No. 2001, Longxiang Avenue, Shenzhen, Guangdong, China

    Hequn Zou

Authors
  1. Yu Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Youqun Huang
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Dongxuan Sun
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Naijing Ye
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Tong Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Mengfan Yang
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Li Zhou
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Hequn Zou
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

Youqun Huang, Dongxuan Sun, Naijing Ye, Tong Chen, MengfanYang, Li Zhou, Hequn Zou contributed equally to this work. Youqun Huang, Dongxuan Sun for providing the article idea,Naijing Ye,,Hequn Zou and Tong Chen for their help in reviewing the article, Mengfan Yang in language polishing, and Li Zhou for help in finding literature.

Corresponding author

Correspondence to Hequn Zou.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Liu, Y., Huang, Y., Sun, D. et al. Research progress of astragaloside IV in treating acute kidney injury. Int Urol Nephrol (2024). https://doi.org/10.1007/s11255-024-04016-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1007/s11255-024-04016-6

Keywords

Search

Navigation